Phase 1/2 study of RP L102 in the patients with Fanconi's-anaemia
Phase of Trial: Phase I/II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs RP L102 (Primary)
- Indications Fanconi's anaemia
- Focus Therapeutic Use
- 28 Nov 2018 According to a Rocket Pharmaceuticals media release, based on the results of this study, the US FDA has ranted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to RP-L102 for the treatment of Fanconi Anemia (FA).
- 01 Nov 2018 Long-term follow up data from the first four patients treated will be presented at American Society of Hematology 2018 Annual Meeting.
- 01 Nov 2018 According to a Rocket Pharmaceuticals media release, Dr. Juan Bueren is a principal investigator of this trial.